Biomarin Pharmaceutical Inc
BMRNFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Biomarin Pharmaceutical Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 18 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 4, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| VOYA INVESTMENT MANAGEMENT LLC | 2026-03-31 | 74,360 | $4.2M | SEC filing |
| RAYMOND JAMES FINANCIAL INC | 2026-03-31 | 331,373 | $18.7M | SEC filing |
| Empowered Funds, LLC | 2026-03-31 | 33,203 | $1.88M | SEC filing |
| Foundations Investment Advisors, LLC | 2026-03-31 | 3,901 | $220K | SEC filing |
| QRG CAPITAL MANAGEMENT, INC. | 2026-03-31 | 5,230 | $295K | SEC filing |
| STATE OF WISCONSIN INVESTMENT BOARD | 2026-03-31 | 121,987 | $6.89M | SEC filing |
| Farther Finance Advisors, LLC | 2026-03-31 | 7,857 | $450K | SEC filing |
| Robeco Institutional Asset Management B.V. | 2026-03-31 | 545,135 | $30.8M | SEC filing |
| FRED ALGER MANAGEMENT, LLC | 2026-03-31 | 3,690 | $208K | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 1,321,665 | $74.7M | SEC filing |
| Swedbank AB | 2026-03-31 | 792,187 | $44.8M | SEC filing |
| TWIN PEAKS WEALTH ADVISORS, LLC | 2026-03-31 | 204 | $11.5K | SEC filing |
| DRW Securities, LLC | 2026-03-31 | 12,426 | $702K | SEC filing |
| SITTNER & NELSON, LLC | 2026-03-31 | 2,700 | $153K | SEC filing |
| WESBANCO BANK INC | 2026-03-31 | 35,000 | $1.98M | SEC filing |
| Meiji Yasuda Life Insurance Co | 2026-03-31 | 10,451 | $590K | SEC filing |
| Financial Management Professionals, Inc. | 2026-03-31 | 35 | $1.98K | SEC filing |
| Louisiana State Employees Retirement System | 2026-03-31 | 55,700 | $3.15M | SEC filing |
| ARIZONA STATE RETIREMENT SYSTEM | 2026-03-31 | 50,131 | $2.83M | SEC filing |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2026-03-31 | 851,556 | $48.1M | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Biomarin Pharmaceutical Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-26 · Davis George Eric: Larger than 31 of the 33 other insider sales of Common Stock on file. SEC filing
- 2024-05-28 · Davis George Eric: Larger than all 33 other insider sales of Common Stock on file. SEC filing
- 2024-03-28 · Davis George Eric: Larger than 30 of the 33 other insider sales of Common Stock on file. SEC filing
- 2024-03-05 · FUCHS HENRY J: Larger than 32 of the 33 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-07 | Friberg Gregory R · EVP, Chief R&D Officer | Common Stock | S — Open market or private sale | −3,281 | 53.85 | SEC filing |
| 2026-03-11 | Guyer Charles Greg · EVP, Chief Technical Officer | Common Stock | S — Open market or private sale | −16,486 | 60.46 | SEC filing |
| 2026-02-26 | Friberg Gregory R · EVP, Chief R&D Officer | Common Stock | S — Open market or private sale | −6,326 | 60.38 | SEC filing |
| 2026-02-26 | Davis George Eric · EVP, Chief Legal Officer | Common Stock | S — Open market or private sale | −26,061 | 61.36 | SEC filing |
| 2025-05-20 | Burkhart Erin · GVP, Chief Accounting Officer | Common Stock | S — Open market or private sale | −1,786 | 59.31 | SEC filing |
| 2025-05-02 | Hubbard Cristin · EVP, Chief Commercial Officer | Common Stock | S — Open market or private sale | −273 | 64.92 | SEC filing |
| 2025-03-19 | Burkhart Erin · GVP, Chief Accounting Officer | Common Stock | S — Open market or private sale | −1,295 | 71.52 | SEC filing |
| 2025-03-06 | Guyer Charles Greg · EVP, Chief Technical Officer | Common Stock | S — Open market or private sale | −7,034 | 71.28 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-02 | CLARK IAN T · Director | Common Stock | A — Grant, award, or other acquisition | +7,490 | SEC filing |
| 2026-06-02 | Enyedy Mark J · Director | Common Stock | A — Grant, award, or other acquisition | +7,490 | SEC filing |
| 2026-06-02 | Bodem Barbara W. · Director | Common Stock | A — Grant, award, or other acquisition | +7,490 | SEC filing |
| 2026-06-02 | Dere Willard H · Director | Common Stock | A — Grant, award, or other acquisition | +7,490 | SEC filing |
| 2026-06-02 | HOMBACH ROBERT J. · Director | Common Stock | A — Grant, award, or other acquisition | +7,490 | SEC filing |
| 2026-06-02 | Ho Maykin · Director | Common Stock | A — Grant, award, or other acquisition | +7,490 | SEC filing |
| 2026-06-02 | Countouriotis Athena · Director | Common Stock | A — Grant, award, or other acquisition | +7,490 | SEC filing |
| 2026-06-02 | ANDERSON ELIZABETH M · Director | Common Stock | A — Grant, award, or other acquisition | +7,490 | SEC filing |
Showing 8 of 35 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2024-01-18 | BIENAIME JEAN JACQUES · Director | Common Stock | L — Small acquisition | +40 | SEC filing |
| 2024-01-08 | BIENAIME JEAN JACQUES · Director | Common Stock | L — Small acquisition | +50 | SEC filing |
| 2023-10-04 | BIENAIME JEAN JACQUES · Director | Common Stock | L — Small acquisition | +10 | SEC filing |
Showing 3 of 3 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.